BLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
Priority Review
OCREVUS (ocrelizumab) by Roche is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2017.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCREVUS (ocrelizumab) is a CD20-directed cytolytic monoclonal antibody approved in March 2017 for treating multiple sclerosis by targeting and depleting B cells. It works through direct antibody-mediated interactions with CD20 antigen on B cell surfaces, reducing inflammation and disease progression. The drug is currently at peak commercial lifecycle with sustained market presence.
$0.157BPart D
PeakProduct is at peak revenue stage with stable claims volume, suggesting mature team structures and focus on market defense and optimization rather than rapid expansion.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Started Oct 2026
25 enrolled
Relapsing-remitting Multiple Sclerosis
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
Started Oct 2026
222 enrolled
Multiple Sclerosis
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Started Sep 2026
100 enrolled
Multiple Sclerosis
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Started Jun 2026
34 enrolled
Multiple SclerosisPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)+8 more
Ocrevus Zunovo for MS: Mixed Methods
Started Jun 2026
150 enrolled
Multiple Sclerosis
Worked on OCREVUS at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.